Cingulate Inc.
CINGNASDAQHealthcareBiotechnology
Previous close
$5.55
+$0.22 · +4.13%
CING company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
29
Expensive
Momentum
37
Weakening
Sentiment
60
Mixed
Risk resilience
37
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteCingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Shane J. Schaffer
- Listed since
- Dec 8, 2021
- Employees
- 14
Market position
Day range
Current $5.55
52-week range
Current $5.55
- Open
- $5.44
- Previous close
- $5.33
- Volume
- 234.69K
- 0.54× average
- Average volume
- 433.38K
- Average daily volume
- Market cap
- 74.75M USD
- Beta
- -0.91
- Market reference 1
- 50-day average
- $4.9658
- +11.76% above average
- 200-day average
- $5.1941
- +6.85% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 21.4M USD
- P/E (TTM)
- -1.27×
- P/B (TTM)
- 3.12×
- P/S (TTM)
- 0×
- EV / EBITDA
- -1.1×
- Earnings yield
- -95.24%
- Free cash flow yield
- -73.85%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -894.81%
- Return on assets
- -148.94%
- Return on invested capital
- -176.51%
Financial health
- Debt / equity
- 52.14×
- Current ratio
- 1.16×
- Altman Z-score
- 5.76
- Piotroski F-score
- 1 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 9.77M USD | 9.45M USD | 15.49M USD | 9M USD | 8.41M USD |
| Selling, general, and administrative | 10.16M USD | 6.2M USD | 7.27M USD | 8.51M USD | 12.27M USD |
| Operating expenses | 19.94M USD | 15.64M USD | 22.76M USD | 17.5M USD | 20.68M USD |
| Interest income | 369.27K USD | — | 775.76K USD | 174.51 USD | — |
| Interest expense | 924.45K USD | — | — | 174K USD | 33.41K USD |
| Depreciation and amortization | 540.89K USD | 653.09K USD | 582.92K USD | 394.01K USD | 708.32K USD |
| Operating income | −19.94M USD | −15.64M USD | −22.76M USD | −17.5M USD | −20.68M USD |
| Net income | −22.45M USD | −16.56M USD | −23.53M USD | −17.68M USD | −20.71M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 36%
- 4 beats, 7 misses, 0 met estimates
- Average EPS surprise
- -17.53%
- 11 comparable reports
- Latest EPS result
- -0.45
- Estimate -0.63 · Beat by 28.00%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
6 ratingsCING news
CING peers
ETFs holding CING
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 1.89M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
Vanguard Extended Market ETFVXF- Market value
- 768.3K
- Weight
- 0.00%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
iShares Micro-Cap ETFIWC- Market value
- 151.15K
- Weight
- 0.01%
- AUM
- 1.53B USD
- Expense ratio
- 0.60%
- Price / 1D
- $198.39+1.10%
Continue in GoAI
Research CINGresearch.disclaimer